Regulatory drug approval: protecting patients or serving impatient shareholders?
- PMID: 34588181
- DOI: 10.1136/bmj.n2382
Regulatory drug approval: protecting patients or serving impatient shareholders?
Conflict of interest statement
Competing interests: AB is among independent industry experts on Jeanne Lenzer’s list (https://jeannelenzer.com/list-independent-experts).
Comment on
-
Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study.BMJ. 2021 Sep 8;374:n1959. doi: 10.1136/bmj.n1959. BMJ. 2021. PMID: 34497044 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources